First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

Forschungsstelle

INNOSUISSE

Projektnummer

121.049 IP-LS

Projekttitel

First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

Projekttitel Englisch

First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Schlüsselwörter	-	-	-
Abstract	-	-	-

Kategorie	Text
Schlüsselwörter (Englisch)	Life sciences, Human medicine
Abstract (Englisch)	Ymmunobio is a biotech firm developing GI cancer therapies targeting the Neuronal Pentraxin Receptor (NPTXR), found in 70-80% of metastatic gastric and colorectal cancers. Their lead product, YB-800, a humanized antibody, is advanced in collaboration with PSI, aiming for clinical proof of concept.